Newseria: – Our main product that we are currently focused on is a transdermal system that increases the bioavailability of active substances. First and foremost, it improves the patient’s comfort during therapy. Our daily tablet intake can be huge, and some patients have to take more than ten or even twenty tablets a day, so the transdermal route seems to be an option as it reduces side effects for the digestive tract, says Paweł Biernat, CEO of Biotts start-up to Newseria Innowacje information agency.
